EyePoint Pharmaceuticals, Inc.
EYPT
$14.52
$0.836.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -0.51% | -31.49% | -9.17% | -41.00% | 4.75% |
| Total Depreciation and Amortization | 7.06% | 8.25% | 6.42% | 14.46% | 12.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.93% | -8.25% | -1.50% | 10.95% | -20.46% |
| Change in Net Operating Assets | 38.89% | 36.00% | -1,222.61% | 92.99% | -576.55% |
| Cash from Operations | 5.17% | -17.83% | -48.18% | 8.15% | -93.42% |
| Capital Expenditure | 34.59% | -342.03% | 28.13% | 75.60% | -74.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 13.37% | 24.51% | 141.64% | -637.86% | 111.14% |
| Cash from Investing | 14.58% | 22.29% | 141.19% | -692.50% | 110.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -68.75% | 54.29% | -9.38% | 56.16% | -- |
| Issuance of Common Stock | 2,670.33% | -53.96% | -99.61% | 1,162.72% | 1,827.04% |
| Repurchase of Common Stock | -600.00% | 98.44% | -- | 100.00% | 0.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 20.27% | -- | 100.00% |
| Cash from Financing | 3,010.50% | 125.03% | -100.63% | 1,175.41% | 3,514.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 124.50% | 3.65% | -173.19% | 281.68% | 93.93% |